|
|
|
31.10.25 - 15:33
|
20% Earnings Growth Potential For DexCom, Analyst Cites Buying Opportunity (Benzinga)
|
|
|
DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead.
Latest Ratings for DXCM
DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022BTIGUpgradesNeutralBuy Jan 2022Wells FargoUpgradesEqual-WeightOverweight
View More Analyst Ratings for DXCM
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
30.10.25 - 23:12
|
DexCom Inc. Q3 Profit Increases, Beats Estimates (AFX)
|
|
|
WASHINGTON (dpa-AFX) - DexCom Inc. (DXCM) reported earnings for its third quarter that Increased from last year and beat the Street estimates.The company's bottom line came in at $283.8 million, o......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.10.25 - 09:33
|
ViCentra Strengthens Leadership Team to Accelerate Growth (PR Newswire)
|
|
|
Karen Baxter , former VP & GM at Dexcom with deep expertise in diabetes device commercialization across Europe, joins as SVP Sales , Europe Jay Little, leader from Medtronic Diabetes, appointed VP Strategy & Business Development Team expansion will drive growth strategy, market......
|
|
|
28.10.25 - 08:06
|
Director Declaration (Cision)
|
|
|
28 October 2025
Director Declaration
AstraZeneca PLC (the Company) today announced that Euan Ashley, Non-Executive Director of the Company, has been appointed a director of DexCom, Inc.with effect from 24 October 2025.
This announcement is made pursuant to Listing Rule 6.4.9 (2).
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory &...
|
|
|
27.10.25 - 21:18
|
Dexcom Appoints Euan Ashley to Board of Directors (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--$DXCM #CGM--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025.
Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-director of Stanford's biomedical innovation-translation program, Catalyst, which invests in the university's most promising biomedical innovations. Dr. Ashley brings to the Dexcom Board a leading clinical perspective for strategic guidance related to medical technology development and...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
